Portfolio company
Mémo Tx
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
The company develops antibody therapeutics for viral infections and cancer to treat patients such as kidney transplant recipients.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
memo therapeutics
The company develops therapeutic antibodies to treat patients with viral infections and cancer using a high-throughput single-cell screening platform.
TigaTx
The company develops engineered immunoglobulin A antibody therapeutics that activate neutrophils to treat patients with cancer and infectious diseases.
SenyaTx
This company develops antibody-based therapeutics targeting the LRG1 protein to treat patients with chronic vascular diseases, including nephrology, oncology, and ophthalmology conditions.
Invivyd
Invivyd develops monoclonal antibody therapies to protect immunocompromised patients from serious viral infectious diseases, including COVID-19 and measles.
Veratx
The company develops medicines for patients with autoimmune diseases, focusing on the treatment of kidney conditions such as IgA nephropathy.
Arxx Therapeutics
This biotechnology firm develops monoclonal antibody therapies for patients suffering from chronic inflammatory and fibrotic diseases.
Mestag Therapeutics
This company develops antibody therapies targeting fibroblast immunology for patients with cancer and inflammatory diseases.
Adagio tx
This biopharmaceutical company develops monoclonal antibody treatments and prophylactics for infectious viral diseases to protect patients against coronaviruses and their evolving variants.